Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| TB Twogee BiotechCompany profile Develops customised enzyme solutions for converting biomass into sustainable raw materials Develops customised enzyme solutions for converting biomass into sustainable raw materials | €2.2M | Seed | Biotech, Climate tech | Germany | Investors | |
| TT Develops treatments to rejuvenate vision in the aging eye | $235M | Series B | Biotech | United States | Investors | |
| PC PranaX CorporationCompany profile Develops exosome-based technologies for regenerative biologics and wellness Develops exosome-based technologies for regenerative biologics and wellness | $17M | Series A | Biotech | United States | Investors Undisclosed | |
| A Builds AI-ready lab automation platforms for life sciences | $45M | Series CSeries C+ | Biotech, Industrial tech | United Kingdom | Investors | |
| P PrenosisCompany profile Develops integrated diagnostics and therapeutics for critical care conditions Develops integrated diagnostics and therapeutics for critical care conditions | $20M | Series A | Biotech | United States | Investors | |
| ET Elysium TherapeuticsCompany profile Develops treatments to prevent and reverse overdoses caused by synthetic opioids Develops treatments to prevent and reverse overdoses caused by synthetic opioids | $7.5M | SAFEUndisclosed | Biotech | United States | Investors Undisclosed | |
| HA Heritable AgricultureCompany profile Develops AI-driven crop improvement solutions for climate-resilient crops Develops AI-driven crop improvement solutions for climate-resilient crops | $5M | GrantUndisclosed | Biotech, Agritech | United States | Investors | |
 CellaresCompany profile Cellares manufactures cell therapies for drug developers using automated production and quality-control systems deployed through its Smart Factory network. Cellares manufactures cell therapies for drug developers using automated production and quality-control systems deployed through its Smart Factory network. | $257M | Series DSeries C+ | Biotech | United States | Investors | |
| SB Stellular BioCompany profile Develops platelet-derived regenerative biologic therapeutics for ocular surface diseases Develops platelet-derived regenerative biologic therapeutics for ocular surface diseases | Undisclosed | Series A | Biotech | United States | Investors | |
| TB Develops precision immunoregulatory medicines based on tissue Treg biology | $50M | Undisclosed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.